Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

15 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
MGMT inhibition in ER positive breast cancer leads to CDC2, TOP2A, AURKB, CDC20, KIF20A, Cyclin A2, Cyclin B2, Cyclin D1, ERα and Survivin inhibition and enhances response to temozolomide.
Bobustuc GC, Kassam AB, Rovin RA, Jeudy S, Smith JS, Isley B, Singh M, Paranjpe A, Srivenugopal KS, Konduri SD. Bobustuc GC, et al. Oncotarget. 2018 Jul 3;9(51):29727-29742. doi: 10.18632/oncotarget.25696. eCollection 2018 Jul 3. Oncotarget. 2018. PMID: 30038716 Free PMC article.
MGMT inhibition restores ERα functional sensitivity to antiestrogen therapy.
Bobustuc GC, Smith JS, Maddipatla S, Jeudy S, Limaye A, Isley B, Caparas ML, Constantino SM, Shah N, Baker CH, Srivenugopal KS, Baidas S, Konduri SD. Bobustuc GC, et al. Mol Med. 2012 Sep 7;18(1):913-29. doi: 10.2119/molmed.2012.00010. Mol Med. 2012. PMID: 22549111 Free PMC article.
New insights into estrogenic regulation of O6-methylguanine DNA-methyltransferase (MGMT) in human breast cancer cells: Co-degradation of ER-α and MGMT proteins by fulvestrant or O6-benzylguanine indicates fresh avenues for therapy.
Paranjpe A, Bailey NI, Konduri S, Bobustuc GC, Ali-Osman F, Yusuf MA, Punganuru SR, Madala HR, Basak D, Mostofa A, Srivenugopal KS. Paranjpe A, et al. Among authors: bobustuc gc. J Biomed Res. 2016 Sep;30(5):393-410. doi: 10.7555/JBR.30.20160040. Epub 2016 Jun 10. J Biomed Res. 2016. PMID: 27845303 Free PMC article.
15 results